CollabRx teams up with University of Chicago Medical Center
SAN FRANCISCO—Data analytics company CollabRx, Inc. has announced that it will be collaborating with the thoracic oncology program at the University of Chicago Medical Center to combine its content and technology with the results of genetic sequencing-based tests performed at the University of Chicago Medical Center. The collaboration will be led by Ravi Salgia, MD, PhD., a professor of medicine and vice chair of translational research at the University of Chicago. These tests allow physicians to consider the unique genetic profile of a tumor while planning cancer treatments.
"We are honored to be working closely with the thoracic oncology program at the University of Chicago Medical Center to build out a full set of capabilities to support a precision oncology approach to cancer treatment planning," Thomas R. Mika, chairman, president and CEO of CollabRx, said in a press release about the partnership. "The goal of our collaboration is nothing less than to improve cancer patient care by unlocking the full potential of next-generation sequencing of patient tumors."
Per the terms of the agreement, CollabRx will make available a turnkey medical informatics solution by combining the results of cancer mutational panels performed by Salgia and his colleagues with clinically actionable and dynamically updated knowledge from CollabRx, which includes the clinical impact of specific mutational profiles and associated therapeutic strategies such as drugs and clinical trials. The resulting solution can be customized by highlighting clinical trials at the University of Chicago that patients may be eligible for based on the genetic signature of their tumor.
"Our program is committed to identifying optimal treatments for cancer patients using a holistic approach," Salgia commented in a statement. "This commitment includes consideration of drugs and other therapies that target genetic abnormalities in tumors. These genetic abnormalities can now be efficiently identified using cancer mutation panels based on next-generation sequencing technologies. CollabRx 's expert systems add substantial value to these panels by infusing interpretation and insight from recognized thought leaders who have a deep knowledge of the latest scientific and medical research in molecular oncology and, more importantly, understand how to apply this knowledge to inform treatment planning at the point of care. We are highly enthusiastic about working with CollabRx to bring its unique capabilities to bear in optimizing patient care for those with thoracic cancers at the University of Chicago Medical Center."
The collaboration comes just a little over a month after CollabRx announced a similar agreement with GeneInsight LLC, in which the partners agreed to deliver a unique medical informatics solution to support the interpretation and reporting of genetic variants from sequencing-based tests.
SOURCE: CollabRx press release